New Hope for Type I Diabetes Patients

Seattle, Washington (PRWEB) January 29, 2013

Patients report success with stem cell treatment for diabetics. Traveling4Health&Retirement (THR) announces their choice of a stem cell surgeon sponsor in Buenos Aires, a popular South America destination location for overseas retirement and medical travel.

We are pleased to promote Dr. Alejandro Mesples as our medical services sponsor in Buenos Aires, said Ilene Little, CEO of Traveling4Health&Retirement.

Dr. Mesples has published several papers in medical journals on the results of his research and therapy and is widely known and accepted as the authority on stem cell based surgery for diabetes using the patients own stem cells.

Recent results of his ongoing research were published 1/22/13 in the latest issue (Vol.3 No.1,2013) of the SCD medical journal, paper ID 1080044.

The sponsor selection was based on patient-generated reviews, interviews with the company leadership, and the strong support for the potential of the therapy and associated research as expressed in letters received from professors at the University of Padua in Italy and a professor of Endocrinology at Johns Hopkins.

When patients rave about their medical outcomes and a providers customer service, that gets our attention, said Ilene Little, We only promote doctors and accept destination sponsorships from doctors whose patients and professional peers recommend their services.

Download and listen, for free, to the father of a nine year old girl describing her stem cell treatment by Dr. Mesples on the 1/15/13 Know Before You Go Show aired on the Overseas Radio Network.

Lara was 8 years old and had a diagnosis of type 1 (or juvenile) diabetes newly diagnosed (one month prior to my prescribing her treatment plan), said Dr. Mesples, In September, 2011, we performed a liver implant of bone marrow stem cells in order to stop the autoimmune attack to the pancreas.

Normally this type of diabetes is secondary to antibody-mediated destruction and its evolution is marked by the increase of antibodies levels, low c peptide (low pancreatic function), and early use of insulin in high doses.

More:
New Hope for Type I Diabetes Patients

Related Post